FINWIRES · TerminalLIVE
FINWIRES

Update: Bausch Health Shares Rise After Higher Q2 Results, Raised 2026 Revenue Outlook

By

(Updates with the latest stock movement in the first paragraph and headline.)

Bausch Health (BHC) shares were up roughly 27% in Thursday trading after the company reported higher Q2 results and raised its 2026 revenue outlook.

The company reported Q2 adjusted earnings late Wednesday of $1.26 per diluted share, up from $0.90 a year earlier.

Analysts polled by FactSet expected $0.99.

Revenue for the quarter ended June 30 was $2.85 billion, compared with $2.53 billion a year earlier.

Four analysts expected $2.61 billion.

For 2026, the company now expects revenue of $10.79 billion to $11.04 billion, up from $10.67 billion to $10.92 billion previously. Four analysts expect $10.52 billion.

Price: $5.98, Change: $+1.30, Percent Change: +27.78%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT